{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:17:39Z","timestamp":1772468259255,"version":"3.50.1"},"reference-count":102,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>The introduction of chimeric antigen receptor T\u2010cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed\/refractory B\u2010cell malignancies. Patients with acute lymphoblastic leukemia and non\u2010Hodgkin\u2019s lymphoma who had exhausted all meaningful treatment options now have an opportunity for long\u2010term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukemia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoing. Such therapeutic success brings challenges in toxicity management related to cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome. Our understanding of these unique syndromes is evolving, with predictive models and additional treatment strategies on the horizon. This review aims to summarize the progress of CAR T therapeutics within malignant hematology thus far and highlight ongoing advances in the field.<\/jats:p>","DOI":"10.1002\/phar.2414","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T03:15:05Z","timestamp":1588907705000},"page":"741-755","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in CAR T Therapy for Hematologic Malignancies"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-8134","authenticated-orcid":false,"given":"Craig W.","family":"Freyer","sequence":"first","affiliation":[{"name":"Department of Pharmacy Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Cell Therapy and Transplant Perelman School of Medicine and the Abramson Cancer Center University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30864-7"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.251"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.10.003"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.97"},{"key":"e_1_2_9_13_1","unstructured":"Kymriah. [Package Insert].East Hanover NJ:Novartis Pharmaceuticals Co.;2017."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0627-z"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1182\/blood-2019-129279","article-title":"Tisagenlecleucel chimeric antigen receptor (CAR) T cell therapy for relapsed\/refractory children and young adults with acute lymphoblastic leukemia (ALL) real world experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) and Cellular Therapy (CT) registry","volume":"134","author":"Grupp S","year":"2019","journal-title":"Blood"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130983"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_9_18_1","unstructured":"Yescarta. [Package insert].Santa Monica CA:Kite Pharma Inc.;2019."},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124750"},{"key":"e_1_2_9_21_1","unstructured":"U.S. Department of Health and Human Services.Common terminology criteria for adverse events (CTCAE) version 4.0. Available fromhttps:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010\u201006\u201014_QuickReference_8.5x11.pdf. Accessed December 10 2019."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.108"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7006"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","unstructured":"WayneAS HuynhV HijiyaN et al.Phase 1 results of ZUMA\u20104: KTE\u2010X19 an anti\u2010CD19 chimeric receptor T cell therapy in pediatric and adolescent patients with relapsed\/refractory B cell acute lymphoblastic lymphoma. EHA Library. S. Wayne A. Jun 15 2019; 267263; PS962. Available fromhttps:\/\/library.ehaweb.org\/eha\/2019\/24th\/267263\/alan.s.wayne.phase.1.results.of.zuma\u20104.kte\u2010x19.an.anti\u2010cd19.chimeric.antigen.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D1%2Amedia%3D1. Accessed December 4 2019.","DOI":"10.1097\/01.HS9.0000562152.07779.48"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0488-7"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127508"},{"key":"e_1_2_9_30_1","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2019.12.093","article-title":"Outpatient treatment with lisocabtagene maraleucel (liso\u2010cel) in 3 ongoing clinical studies in relapsed\/refractory (R\/R) large B cell non\u2010Hodgkin lymphoma (NHL), including second\u2010line transplant noneligible (TNE) patients: TRANSCEND NHL 001, outreach, and PILOT","volume":"26","author":"Bachier CR","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.3769.3769"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001694"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.6637"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1704610"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129097"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123765"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127684"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121731"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30115-2"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129405"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126689"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130340"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5415"},{"key":"e_1_2_9_48_1","first-page":"1","article-title":"Long\u2010term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey NV","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519"},{"key":"e_1_2_9_50_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2019-127603","article-title":"Rapid undetectable MRD (uMRD) responses in patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) treated with lisocabtagene maraleucel (liso\u2010cel), a CD19\u2010directed CAR T cell product: updated results from Transcend CLL 004, a phase 1\/2 study including patients with high\u2010risk disease previously treated with ibrutinib","volume":"134","author":"Siddiqi T","year":"2019","journal-title":"Blood"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.137"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.262"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-115418"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.074"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-837609"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111202"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815105"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60485-1"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121486"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2016-0127"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0247-0"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000017"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129411"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127640"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.036"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119502"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112572"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.314"},{"key":"e_1_2_9_72_1","first-page":"1319","article-title":"Durable remissions with humanized CD19\u2010targeted chimeric antigen receptor (CAR)\u2010modified T cells in CAR\u2010na\u00efve and CAR\u2010exposed children and young adults with relapsed\/refractory acute lymphoblastic leukemia","volume":"130","author":"Maude SL","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.038"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.04.001"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881722"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.227"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01892"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.105"},{"key":"e_1_2_9_83_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi\u2010cel; KTE\u2010C19) treatment for patients with refractory, aggressive non\u2010Hodgkin lymphoma (NHL)","volume":"130","author":"Locke FL","year":"2017","journal-title":"Blood"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.436"},{"key":"e_1_2_9_85_1","unstructured":"Actemra. [Package insert].South San Francisco CA:Genentech Inc.;2017."},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30156-5"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000001402"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4095-1"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"e_1_2_9_95_1","first-page":"P217","article-title":"Clinical outcomes for the phase 2, single\u2010arm, multicenter trial of JCAR015 in adult B\u2010ALL (ROCKET Study)","volume":"5","author":"DeAngelo DJ","year":"2017","journal-title":"J Immunother Cancer"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25315"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-12-893396"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.12.603"},{"key":"e_1_2_9_101_1","unstructured":"Memorial Sloan Kettering Cancer Center.A study of anakinra to prevent or treat severe side effects for patients receiving CAR\u2010T cell therapy. Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04148430?term=anakinra+and+chimeric+antigen&draw=2&rank=2. Accessed March 27 2020."},{"key":"e_1_2_9_102_1","unstructured":"Kite Pharma.Study of lenzilumab and axicabtagene ciloleucel in participants with relapsed or refractory large B\u2010cell lymphoma (ZUMA\u201019). Available fromhttps:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04314843?term=lenzilumab&draw=2&rank=2. Accessed March 27 2020."},{"key":"e_1_2_9_103_1","unstructured":"U.S. Department of Health and Human Services.Common terminology criteria for adverse events (CTCAE) version 4.0. Available fromhttps:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 10 December 2019."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2414","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2414","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2414","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:09:07Z","timestamp":1761059347000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":102,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1002\/phar.2414"],"URL":"https:\/\/doi.org\/10.1002\/phar.2414","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"2020-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}